

# Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia

Arican I, Bass N, Neelam K, Wolfe K, McQuillin A, Giaroli G.  
Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia.

**Objective:** To investigate the frequency of childhood and adult attention deficit hyperactivity disorder (ADHD) symptoms in a cohort of patients with schizophrenia (SCZ).

**Methods:** A systematic review was conducted to evaluate existing evidence. Two self-report questionnaires were used to investigate adult ADHD and childhood ADHD symptoms in 126 patients with ICD-10 diagnoses of SCZ.

**Results:** Five studies were included in the systematic review, with the prevalence of childhood and adult ADHD in SCZ subjects ranging between 17–57% and 10–47% respectively. Within our cohort, 47% of patients reported positive screening for ADHD symptoms either in childhood or adulthood. 23% reported symptomatology consistent with both childhood and adult ADHD.

**Conclusions:** We demonstrate a greater presence of ADHD symptomatology in SCZ compared to that reported for ADHD in the general population. Our findings highlight the importance of improved clinical assessment and treatment considerations in a subgroup of patients with SCZ.

I. Arican<sup>1</sup> , N. Bass<sup>1</sup>,  
K. Neelam<sup>2</sup>, K. Wolfe<sup>1</sup>,  
A. McQuillin<sup>1</sup>, G. Giaroli<sup>1</sup>

<sup>1</sup>Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, London, and <sup>2</sup>Greater Manchester Mental Health NHS Foundation Trust, Bolton, UK

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

[Copyright line has been updated after first online publication on 7 September 2018].

Key words: cognitive impairment; comorbidity; psychoses; diagnosis; ADHD

Izemnur Arican, Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, Gower Street, London, WC1E 6BT, UK.  
E-mail: izemnur.arican.14@ucl.ac.uk

Accepted for publication July 20, 2018

## Significant outcomes

- 23% of patients with schizophrenia report childhood and adult attention deficit hyperactivity disorder symptoms compared to 2.5% of adults diagnosed in the general population.

## Limitations

- The questionnaires are not diagnostic.
- Patients in the sample were not screened for active SCZ or mood symptoms.
- The lack of a new control group from the general population for comparison purposes.

## Introduction

Schizophrenia (SCZ) and attention deficit hyperactivity disorder (ADHD) are both neurodevelopmental disorders. SCZ is defined by the presence of psychotic symptoms, disorganised speech/behaviour and negative symptoms, such as avolition and alogia (1). However, neurocognitive deficits are

increasingly recognised as a core feature of SCZ, associated with functional outcomes (2) and quality of life (3, 4). SCZ has a population prevalence of approximately 1% (5), with a male-to-female ratio of 1.4 : 1 (6). ADHD is a behavioural disorder characterised by pervasive and impairing symptoms of inattention, hyperactivity and impulsivity before the

age of 12 (7). The prevalence in children aged 18 or younger is estimated to be 5.29% (8), with a male-to-female ratio of 4 : 1 in the general population (9). Diagnostic follow-up studies have confirmed ADHD can persist into adulthood with an estimated prevalence of 2.5% in the adult population (10). Furthermore, the symptoms of ADHD in childhood and their persistence into adulthood have been reported to be 10.1% and 4.6%, respectively, in a general adult population (11).

The presentation of SCZ can include varying degrees of attentional dysfunction (12, 13), a central cognitive deficit observed in patients with SCZ (2). Recent work has revealed a genetic correlation between SCZ and ADHD, meaning that there is some overlap between the risk alleles for SCZ and for ADHD (14). Specifically, the genetic correlation ( $r_g$ ) between the two disorders has been estimated to be 0.122 ( $P = 0.0007$ ) (15). Prodromal attention deficit symptoms have retrospectively been identified in patients with SCZ (16), and a prospective study in a Danish cohort has shown that a diagnosis of ADHD is a strong risk factor (RR 4.3) for the development of SCZ (17). Additionally, an odds ratio of 6.7 (95% CI 5.9–7.5) for probands with ADHD to develop SCZ was reported in a Swedish cohort (18). Furthermore, the most common comorbid condition found in childhood-onset SCZ is ADHD, at 84% (19). Thus, ADHD-like features have been suggested to be an early vulnerability marker for SCZ (20).

Aims of the study

We aimed to:

- (i) Systematically review studies that have estimated the prevalence of childhood and adult ADHD in patients with schizophrenia
- (ii) Estimate the prevalence of childhood and adult attention deficit hyperactivity disorder symptoms in a cohort of patients diagnosed with schizophrenia (UCL genetics of schizophrenia cohort).

## Methods

Systematic review of prevalence of ADHD in people with schizophrenia

We systematically reviewed the literature relating to the prevalence of childhood ADHD (cADHD) and the persistence in adulthood of the condition (c+aADHD) in patients with SCZ using the PRISMA criteria (21). Eligible studies included

patients with a SCZ spectrum disorder as defined by DSM-IV or DSM-V or ICD-10 (the 10<sup>th</sup> revision of the International Statistical Classification of Disease and Related Health Problems) (22).

MEDLINE and PsycINFO were searched via OvidSP using the terms: ([Attention deficit hyperactivity disorder] OR [ADHD] AND [Schizophrenia] AND [Prevalence]) on, 29 May 2018. A manual search of the literature was also conducted. Only studies reported in English were considered for the review. Study selection was performed by two reviewers (IA and GG).

The outcome measures were the percentage of patients with SCZ that had a clinical diagnosis of ADHD or ADHD symptoms, as determined by interviews and self-report. A data extraction table capturing the relevant information was developed. Data items extracted included: the number of trial participants, the age range of participants, method of diagnosis of trial participants, methods for assessing the occurrence of ADHD symptoms in trial participants and the outcome measure of prevalence.

Estimation of prevalence of ADHD symptoms in UCL genetics of schizophrenia cohort

*Participants.* The SCZ cohort of the UCL DNA Polymorphisms in Mental Illness (DPIM) has been described previously (23). Briefly, participants were recruited from NHS services. Potential participants with an ICD-10 diagnosis of schizophrenia were interviewed using the Schedule for Affective Disorders and Schizophrenia-Lifetime version (SADS-L) (24), and the 90-item Operational Criteria Checklist (OPCRIT) was also completed (25). Participants who achieved a Research Diagnostic Criteria (RDC) (26) diagnosis of schizophrenia with the SADS-L were included. Ethical approval was granted for the study by the NHS National Research Ethics Service, NRES Committee South Central – Southampton A (formally the Metropolitan Multi-centre Research Ethics Committee) REC Reference Number: 03/11/090. Written informed consent was obtained from each participant. For the SCZ and attention deficit and hyperactivity symptom study described here, 1000 participants from the SCZ cohort of the UCL DPIM study were invited to participate by letter.

*Assessment of ADHD symptoms.* Validated tools were used for the assessment of cADHD symptoms and adult ADHD symptoms (aADHD). The 25-item version of the Wender Utah Rating Scale (WURS) provided information about symptomatology consistent with cADHD based on DSM

criteria (27). The part-A screening test from the Adult ADHD Self-Report Scale (ASRS) was utilised to identify the presence of symptoms consistent with aADHD (28).

OPCRIT and/or SADS-L data were available for 106 of 126 of the participants with SCZ. The earliest age when medical advice was sought or the age of onset of first psychiatric condition (AOO), the age at study entry (ASE), the presence of cannabis abuse/dependence, the presence of alcohol abuse/dependence, the presence of any abuse/dependence (cannabis/alcohol/other), a family history of SCZ, a family history of other psychiatric condition and the length of schooling were extracted from the phenotypic data and used as covariates.

#### Statistical analysis

Stata (version 14) was used for all statistical analyses (29). Data cleaning was performed. Responses were checked for missing or inconsistent data. Participants who returned more than three missing answers on the WURS or more than one on the ASRS were excluded.

The total scores for the WURS and ASRS were calculated for each participant. Data imputation was performed using the subject's average score for the questionnaire affected. A suitable cut-off for each scale was applied to dichotomise the data for analysis. As there was no evidence for the best WURS cut-off score in patients with SCZ, we used a cut-off at 46 of 100 due to its greater discriminatory power in patients with unipolar depression (27).

The ASRS has a maximum score of 30 (six questions with maximum score of 5). Each question has a different 'cut-off' for what is classified as a significant symptom, so for one question it might be 3/5 and for the other 4/5. If a person achieves the cut-off in four of the six questions, they are considered to have symptoms that are highly consistent with ADHD in adults, warranting further clinical investigation (28). In order to implement a questionnaire-wide cut-off score, each question was coded to either 1 or 0 depending on whether its cut-off was reached. Scores of 4 and above were considered positive, and less than 4 were considered to be negative.

To compare the means of continuous variables, we utilised either the t-test or the nonparametric Mann–Whitney *U*-test following assessment for normality. A one-way analysis of variance was used to compare groups of participants with different lifetime prevalences of ADHD symptomatology for AOO and ASE. Linear regression of these covariates with WURS and ASRS scores was also carried out to confirm the association.

The Mann–Whitney *U*-test was utilised to compare whether scoring of each questionnaire was affected by different covariates. To confirm these findings, linear regression was carried out on those covariates that produced indicative significance at the 5% level.

## Results

### Systematic review findings

The systematic search identified 299 studies. After removal of duplicates, and filtering to English-only studies, 226 studies remained. Title and abstract screening identified 10 studies for detailed review. Five articles fulfilled our inclusion criteria, three following the above literature search and 2 from a manual search of databases and reference lists of articles.

Prevalence estimates for cADHD in patients affected by SCZ ranged from 17 to 57%. Only two studies measured the prevalence of ADHD comorbidity in adulthood, reporting 10% and 47%, respectively, see Table 1 (30, 31). Table 2 details the study characteristics of each eligible study.

### Prevalence of lifetime ADHD symptoms in UCL genetics of schizophrenia cohort

Consent-to-participate forms were received from 194 of the 1000 participants invited to take part. Questionnaires were received from 131 subjects; 5 (3.8%) had to be excluded due to the level of missing data leaving a final sample size of 126 (83 (65.9%) men and 43 (34.1%) women). Of these participants, 10 (7.9%) required imputation for one value, 9 (7.1%) for two values and 3 (2.4%) for three missing values. Participants included in the study were aged 21–85.

Twenty-three per cent of participants with SCZ reported symptoms of ADHD in childhood persisting through to adulthood. Symptoms of cADHD only were reported by 11.1%, and aADHD only by 12.7%. The remaining 53.2% of participants reported no ADHD symptoms. In

Table 1. Prevalence of cADHD and/or aADHD reported in the current literature for patients with SCZ

Author/Source	Reported prevalence	Sample (N)
Peralta et al. (2011) (33)	17% cADHD	112
Dalteg et al. (2014) (31)	57% cADHD	119
	47% cADHD + aADHD	
	50% cADHD	247
Rubino et al. (2009) (34)	42.6% cADHD	197
Hallerbäck et al. (2014) (30)	10% cADHD + aADHD	41
Donev et al. (2011) (32)	44.4% cADHD	27

cADHD, childhood ADHD; aADHD, adulthood ADHD.

Table 2. The study characteristics of the five eligible studies included in the systematic review

Source	No. of patients (M)	Age range	Inclusion criteria	Exclusion criteria	Diagnostic tools
Peralta et al. (2011) (33)	112	15–65 years	Patients admitted for treatment of first episode of psychosis and met a DSM-IV diagnosis of schizophrenia, schizopreniform or schizoaffective disorder. Patients had no previous exposition to antipsychotics and an available biological mother.	A history of drug dependence, IQ < 70, evidence of organic brain disorder or any other meaningful medical illness.	An 18-item checklist that included DSM-IV criteria for ADHD was completed by mothers, regarding the ages of 6–10 years. This was then reviewed by researchers who also enquired about age of onset, severity and prior ADHD diagnoses
Dalteg et al. (2014) (31)	119 inpatient ward	16–68 years	In-patients who met DSM-IV criteria for SCZ	The samples excluded drug-induced psychoses	Subjects were interviewed by experienced psychologist and a clinical researcher about childhood symptoms. The self-report Malmö questionnaire assessed adult ADHD (includes the 18 DSM-IV criteria)
	149 Aftercare Sample 2 forensic	20–75 years	Men with a DSM-IV-TR SCZ diagnosis were recruited from forensic psychiatric clinics when released from compulsory care.		All patients were assessed by experienced and trained interviewers. Retrospective cADHD diagnosis was based on the presence of a typical pattern of problems (at time of data collection, there was no ADHD SCID interview)
	98 Aftercare Sample 3 -general clinics	19–63 years	Control patients were of the same age, sex and released from general psychiatry clinics near Sample 2 clinics and had a DSM-IV-TR SCZ diagnosis		
Rubino et al. (2009) (34)	197	35.5 mean (SD = 11.1)	In-patients with DSM-IV diagnoses of adult-onset SCZ	Schizophreniform, schizoaffective and delusional disorders were excluded, patients scoring less than 24 on the Mini Mental State Examination and with clinical evidence of brain damage/disease Their clinical diagnosis had to be confirmed by the SCID-I, or participants were excluded	Two senior psychiatrists employed the SCID interview for current diagnosis. The semistructured interview K-SADS-PL was used to retrospectively identify Axis I disorders in childhood and adolescence With a SCID interview, participants were asked about prior diagnostic assessments, and specifically whether they had been examined for, or had a clinical diagnosis of ADHD The 25-item version of the WUPRS was used to measure ADHD, with a cut-off at 30
Hallerbäck et al. (2014) (30)	41	28.9 mean (SD = 4.6)	All participants provided informed consent and were recruited from the only adult psychiatric clinic in Värmland, Sweden.	Exclusion criteria included any severe psychotic symptoms, medication-induced psychomotor retardation, severe schizophrenic residual symptoms or a comorbid affective disorder	
Donev et al. (2011) (32)	27	18–44 years	All patients had a schizophrenic disorder according to ICD-10 criteria. Informed consent was obtained, and tests were carried out a few days before discharge (likely to be in remission)		

Table 3. Prevalence of cADHD and/or aADHD symptomatology reported by patients with SCZ in the UCL genetics of schizophrenia cohort

Lifetime ADHD symptomatology	Freq: (N = 126)	Per cent (%)	Age range	Gender N (%) male
c+aADHD	29	23.0	23–77	19 (65.5)
aADHD only	16	12.7	35–70	10 (62.5)
cADHD only	14	11.1	29–65	9 (64.3)
No ADHD	67	53.2	21–85	45 (67.2)

cADHD, childhood ADHD symptomatology; aADHD, adulthood ADHD symptomatology; c+aADHD, child and adulthood ADHD symptomatology.

total, 34.1% of 126 subjects with SCZ reported symptomatology consistent with childhood ADHD. Table 3 shows the breakdown of each category for ADHD symptomatology.

As part of the phenotypic data set collected for the DPIM study, information on the AOO was available for 106 participants and ASE for 99. A one-way analysis of variance revealed no significant difference in the AOO ( $P = 0.60$ ) or ASE ( $P = 0.40$ ) in any of the four ADHD symptom groups (cADHD, aADHD, c+aADHD and no ADHD). A linear regression of AOO with ASRS or WURS scores also showed no significance ( $P < 0.05$ ).

#### Secondary analyses

OPCRIT and SADS-L variables were selected to examine their influence on mean WURS and ASRS scores, as shown in Table 4.

Univariate linear regression analyses were carried out for variables with significant associations at the 5% level in Table 4. Regression for the history of any substance abuse with WURS ( $P = 0.0071$ ) and ASRS ( $P = 0.0015$ ) was significant, and a linear regression of ASRS scores on a history of alcohol abuse showed a significant association,  $F(1, 99) = 8.99$ ,  $P = 0.0034$ .

#### Discussion

A systematic review of the published literature of ADHD symptomatology in schizophrenia patients identified only five previous studies, with small sample sizes and heterogeneous study methodologies. For example, Hallerbäck et al. and Donev et al. had a sample size of 41 and 27 patients respectively (30, 32). There were also differences between studies in the criteria used to define ADHD. For example, Dalteg et al. (31) defined ADHD by a ‘typical pattern of problems’ and Donev et al. (32) adopted a less stringent cut-off value for the WURS. The studies also varied in the ascertainment method of schizophrenia patients. For example, Peralta et al. (2011) included patients suffering from first episode SCZ spectrum psychosis (33), Rubino et al. (2009) included inpatients with adult-onset SCZ (34), and Hallerbäck et al. (2014) included patients ascertained from an adult psychiatric clinic (30). The majority of studies only assessed cADHD symptoms in patients with SCZ and therefore were susceptible to recall bias. Only two studies investigated the prevalence of ADHD comorbidity. The ADHD symptom prevalence results from our study fall in the mid-range for prevalence of both c+aADHD and cADHD reported in the literature for people suffering from SCZ (Table 1).

In our cohort, we found 23% of participants with SCZ to have symptomatology consistent with c+aADHD, increasing to 34.1% when including cADHD only. Despite the heterogeneity in the studies of ADHD in SCZ, all estimates of ADHD prevalence and our estimate of symptomatology indicate that ADHD is more common in SCZ than in the general population. The general population prevalence of ADHD diagnosis has been estimated to be 5.3% in childhood and 2.5% in adults (8, 10). This rises to 10.1% for cADHD and 4.6% for c+aADHD in a general population sample from Germany (limited to 18- to 64-year-

Table 4. Mean WURS and ASRS scores with the presence of covariates in the UCL genetics of schizophrenia cohort

Covariate	N	WURS		ASRS	
		Mean score	Analyses	Mean score	Analyses
History of alcohol dependence: Y/N	101	Y: 47.6 (6.8) N: 34.8 (2.4)	$U = 11555.7 P = 0.062$	Y: 20.7 (1.6) N: 16.4 (0.5)	$U = 11514.6 P = 0.015^*$
History of cannabis dependence: Y/N	71	Y: 41.5 (8.0) N: 37.6 (3.0)	$U = 3022.4 P = 0.48$	Y: 19.8 (2.4) N: 17.4 (0.7)	$U = 3012.3 P = 0.26$
History of any abuse/dependence: Y/N	106	Y: 48.3 (5.5) N: 32.8 (2.3)	$U = 14730.9 P = 0.0048^*$	Y: 20.6 (1.3) N: 16.5 (0.5)	$U = 14673.3 P = 0.0043^*$
Education-A high school graduate: Y/N	73	Y: 35.5 (2.9) N: 46.4 (7.6)	$U = 5091.2 P = 0.14$	Y: 17.5 (0.7) N: 18.4 (1.8)	$U = 5069.0 P = 0.47$

WURS, Wender Utah Rating Scale; ASRS, Adult ADHD Self-Report Scale; Y/N Yes/No; \*: Significant at 5% level, statistical comparison utilised the Mann–Whitney  $U$ -test.



olds) where the WURS and ASRS were used to estimate prevalence (11). In our study, 35.7% of participants reported ADHD symptoms in adulthood, and this is higher than reported estimates of adult ADHD symptomatology in the general population of 5.7–10.9% obtained using the ASRS (35–37).

Current diagnostic criteria for ADHD require the onset of symptoms in childhood, that is, before the age of 12 in DSM-5 and before the age of 7 according to the ICD-10. Interestingly, although 35.7% of participants with SCZ reported aADHD symptoms, 12.7% did not report symptomatology suggestive of cADHD. Longitudinal studies of epidemiological cohorts in Brazil (38), UK (39) and New Zealand (40) have recently reported the presence of adult-onset ADHD in the absence of childhood-onset ADHD. This provides support for a model whereby adult-onset ADHD is not necessarily a continuation of childhood-onset ADHD, suggesting that there may be distinct developmental trajectories. It remains unclear whether adult-onset ADHD is a separate diagnostic entity or whether it is an artefact of misdiagnosis or overlapping criteria (methodological bias). Ideally, a diagnosis in an adult is a process that should include a retrospective analysis of the ADHD symptoms in childhood. We find the same results as the longitudinal epidemiological ADHD studies, whereby only a proportion of patients with SCZ meet the criteria for adult-onset ADHD and this would be an important group to study in further research.

Despite AOO being conceptualised as a surrogate measure of severity (41), and an earlier age of onset being associated with more severe cognitive impairments in SCZ (42), our results did not suggest a significant association between age of onset of SCZ and ADHD symptoms. There was also no evidence that the age at which people entered the study influenced their childhood or adult ADHD scores suggesting that this was not a major factor that influenced recall of symptoms. In line with the literature, higher ADHD scores were predictive of a history of any abuse/dependence (43) and were implicated in poorer outcome and treatment compliance in SCZ (44). Also in line with the literature are the findings that participants reporting aADHD symptoms are more vulnerable to alcohol abuse (45). Thus, diagnosing comorbidities in clinical practice could help to identify those most at risk of poorer outcomes and improve interventions and support.

There is currently a lack of recommended pharmacological treatments for people experiencing comorbid SCZ and ADHD (46). SCZ is primarily treated with dopamine D2-antagonists or partial

agonists that are often classed as typical or atypical antipsychotics. ADHD in contrast is treated with ‘dopamine enhancers’, through blockers of the presynaptic dopamine transporter (DAT) and/or noradrenalin transporters (47). Furthermore, patients with comorbid ADHD fail to respond to antipsychotics for their SCZ have poorer outcomes (48) and are vulnerable to the lack of treatment focus on the cognitive impairments seen in patients with SCZ (49). Reports have suggested that psychostimulants typically used in ADHD can alleviate the negative symptoms (50) and cognitive deficits (51) of SCZ; however, there is evidence showing their potential dangers in triggering psychotic symptoms, leaving room for further debate (52, 53). None of the participants in our study reported being prescribed psychostimulants.

This study has multiple limitations which must be acknowledged. First, the sample size was modest, but is similar to comparable studies in the literature. More precise estimates of the prevalence of cADHD and/or aADHD in SCZ will require much larger sample sizes. Second, the sample comprised of participants who volunteered to take part in the DPIM study and responded to the invitation to take part in the study extension exploring the prevalence of inattentiveness, hyperactivity or impulsiveness in people living with schizophrenia. The response rate was below 20%. Moreover, the participants had to complete and return two letters. These factors likely biased the cohort towards people with higher levels of functioning and may impact the applicability of the study data to other settings.

Third, the gold standard assessment for ADHD in adults is the Diagnostic Interview for ADHD in Adults (DIVA) (54); however, we did not specifically aim to diagnose ADHD in our cohort but aimed to assess ADHD symptomatology as a measurement of a continuous variable. Furthermore, we were not able to conduct face-to-face interviews. Fourth, we did not have a measure of current SCZ symptomatology when ADHD symptoms were assessed. Additionally, current mood symptoms were not assessed, which may also have had an effect on ADHD symptom scores, and the WURS is vulnerable to recall bias. Another limitation is that the ASRS has not been validated in patients with SCZ. This might lead to the risk of methodical overlap between symptoms that are more relevant to ADHD with those that are more relevant to SCZ or to functional cognitive impairment. Moreover, we opted to include only part A of the ASRS which has been shown to have a positive predictive value of up to 94.7 at detecting clinical cases of adult ADHD (28). Our decision was guided by the aim of

keeping our questionnaire items to the lowest possible number, in order to maximise responses. By doing so, however, we recognise the reduced ability to perform ADHD subtyping. Future work using the full 18-item ASRS in participants suffering from SCZ has the potential to reveal interesting and important insight into subtypes of ADHD that are observed in SCZ.

We report a higher prevalence of ADHD symptoms in patients with SCZ, as compared to the prevalence of ADHD symptoms within the general population. These findings likely reflect a degree of overlapping symptomatology for the two disorders and also some of the shared genetic aetiology that has been identified in recent genomewide association studies (15). The importance of these findings lies in the contrasting therapies recommended for each condition.

### Acknowledgements

The authors would like to thank the participants who gave freely of their time to take part in the research. We would also like to thank the National Institute for Health Research, Mental Health Research Network and NHS mental health trusts across the UK for their assistance in participant recruitment. Drs McQuillin and Bass are supported by the UCLH NIHR BRC, K Wolfe was funded by a Medical Research Council PhD studentship - MR/K501268-1.

### Declaration of interest

Dr Giovanni Giaroli has received honoraria for acting as a consultant and speaker and for travelling by Shire, Eli Lilly, Flynn Pharma and Janssen.

### References

- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th edn). Arlington, VA: American Psychiatric Association; 2013. 20, 31-32, 87-88, 100-104, 155-165.
- GREEN MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry* 1996;**153**:321-330.
- SAVILLA K, KETTLER L, GALLETLY C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. *Aust New Zeal J Psychiatry* 2008;**42**:496-504.
- UEOKA Y, TOMOTAKE M, TANAKA T et al. Quality of life and cognitive dysfunction in people with schizophrenia. *Prog Neuro-Psychopharmacol Biol Psychiatry* 2011;**35**:53-59.
- CARPENTER WT, BUCHANAN RW. Schizophrenia. *N Engl J Med* 1994;**330**:681-690.
- MCGRATH J, SAHA S, CHANT D, WELHAM J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol Rev* 2008;**30**:67-76.
- EPSTEIN JN, LOREN REA. Changes in the definition of ADHD in DSM-5: subtle but important. *Neuropsychiatry (London)* 2013;**3**:455-458.
- POLANCZYK G, de LIMA MS, HORTA BL, BIEDERMAN J, ROHDE LA. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. *Am J Psychiatry* 2007;**164**:942-948.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th edn.). Arlington, VA: American Psychiatric Association 2000; **210**: 373-374.
- SIMON V, CZOBOR P, BALINT S, MESZAROS A, BITTER I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *Br J Psychiatry* 2009;**194**:204-211.
- BERGER NAA, MÜLLER A, BRÄHLER E, PHILIPSEN A, de ZWAAN M. Association of symptoms of attention-deficit/hyperactivity disorder with symptoms of excessive exercising in an adult general population sample. *BMC Psychiatry* 2014;**14**:250.
- GREEN MF, HARVEY PD. Cognition in schizophrenia: past, present, and future. *Schizophr Res Cogn* 2014;**1**:e1-e9.
- NUECHTERLEIN KH, DAWSON ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. *Schizophr Bull* 1984;**10**:160-203.
- HAMSHERE ML, STERGIAKOULI E, LANGLEY K et al. Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. *Br J Psychiatry* 2013;**203**:107-111.
- DEMONTIS D, WALTERS RK, MARTIN J et al. Discovery of the first genome-wide significant risk loci for ADHD. *Nat Genet* 2000.
- SILVERSTEIN ML, MAVROLEFTEROS G, TURNBULL A. Premorbid factors in relation to motor, memory, and executive functions deficits in adult schizophrenia. *Schizophr Res* 2003;**61**:271-280.
- DALSGAARD S, MORTENSEN PB, FRYDENBERG M, MAIBING CM, NORDENTOFT M, THOMSEN PH. Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. *Eur Psychiatry* 2014;**29**:259-263.
- LARSSON H, RYDÉN E, BOMAN M, LÅNGSTRÖM N, LICHTENSTEIN P, LANDÉN M. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. *Br J Psychiatry* 2013;**203**:103-106.
- ROSS RG, HEINLEIN S, TREGELLAS H. High rates of comorbidity are found in childhood-onset schizophrenia. *Schizophr Res* 2006;**88**:90-95.
- KESHAVAN MS, SUJATA M, MEHRA A, MONTROSE DM, SWEEENEY JA. Psychosis proneness and ADHD in young relatives of schizophrenia patients. *Schizophr Res* 2003;**59**:85-92.
- LIBERATI A, ALTMAN DG, TETZLAFF J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;**339**:b2700.
- BRÄMER GR. International statistical classification of diseases and related health problems. Tenth revision. *World Health Stat Q* 1988;**41**:32-36.
- FIORANTINO A, SHARP SI, MCQUILLIN A. Association of rare variation in the glutamate receptor gene SLC1A2 with susceptibility to bipolar disorder and schizophrenia. *Eur J Hum Genet* 2015;**23**:1200-1206.
- ENDICOTT J, SPITZER RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. *Arch Gen Psychiatry* 1978;**35**:837-844.
- MCGUFFIN P, FARMER A, HARVEY I. A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. *Arch Gen Psychiatry* 1991;**48**:764-770.

26. SPITZER RL, ENDICOTT J, ROBINS E. Research diagnostic criteria: rationale and reliability. *Arch Gen Psychiatry* 1978;**35**:773–782.
27. WARD MF, WENDER PH, REIMHERR FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. *Am J Psychiatry* 1993;**150**:885–890.
28. KESSLER RC, ADLER L, AMES M et al. The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. *Psychol Med* 2005;**35**:245–256.
29. StataCorp. Stata statistical software: release 14. College Station, TX: StataCorp LP; 2015.
30. HALLERBÄCK MU, LUGNEGARD T, GILLBERG C. ADHD and nicotine use in schizophrenia or asperger syndrome: a controlled study. *J Atten Disord* 2014;**18**:425–433.
31. DALTEG A, ZANDELIN A, TUNINGER E, LEVANDER S. Psychosis in adulthood is associated with high rates of ADHD and CD problems during childhood. *Nord J Psychiatry* 2014;**68**:560–566.
32. DONEV R, GANTERT D, ALAWAM K et al. Comorbidity of schizophrenia and adult attention-deficit hyperactivity disorder. *World J Biol Psychiatry* 2011;**12**:1562–2975.
33. PERALTA V, de JALÓN EG, CAMPOS MS, ZANDIO M, SANCHEZ-TORRES A, CUESTA MJ. The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis. *Schizophr Res* 2011;**126**:28–35.
34. RUBINO A, FRANK E, CROCE NANNI R et al. A comparative study of axis I antecedents before age 18 of unipolar depression, bipolar disorder and schizophrenia. *Psychopathology* 2009;**42**:325–332.
35. STICKLEY A, KOYANAGI A, TAKAHASHI H, KAMIO Y. ADHD symptoms and pain among adults in England. *Psychiatry Res* 2016;**246**:326–331.
36. DAS D, CHERBUIN N, BUTTERWORTH P, ANSTEY KJ, EASTEAL S. A population-based study of attention deficit/hyperactivity disorder symptoms and associated impairment in middle-aged adults. *PLoS ONE* 2012;**7**:e31500.
37. ALAHEINO L, LEPPÄMÄKI S. Prevalence of ADHD symptoms among adults in the general population in Finland. *Eur Psychiatry* 2017;**41**:S352.
38. CAYE A, ROCHA TB-M, ANSELMINI L et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood. *JAMA Psychiatry* 2016;**73**:705.
39. AGNEW-BLAIS JC, POLANCZYK GV, DANESE A, WERTZ J, MOFFITT TE, ARSENEAULT L. Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. *JAMA Psychiatry* 2016;**73**:713.
40. MOFFITT TE, HOUTS R, ASHERSON P et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. *Am J Psychiatry* 2015;**172**:967–977.
41. DELISI LE. The significance of age of onset for schizophrenia. *Schizophr Bull* 1992;**18**:209–215.
42. HOFF AL, HARRIS D, FAUSTMAN WO et al. A neuropsychological study of early onset schizophrenia. *Schizophr Res* 1996;**20**:21–28.
43. WILENS TE, MORRISON NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. *Curr Opin Psychiatry* 2011;**24**:280–285.
44. WINKLBAUR B, EBNER N, SACHS G, THAU K, FISCHER G. Substance abuse in patients with schizophrenia. *Dialogues Clin Neurosci* 2006;**8**:37–43.
45. SMITH BH, MOLINA BSG, PELHAM WE. The clinically meaningful link between alcohol use and attention deficit hyperactivity disorder. *Alcohol Res Heal* 2002;**26**:122–129.
46. PALLANTI S, SALERNO L. Raising attention to attention deficit hyperactivity disorder in schizophrenia. *World J Psychiatry* 2015;**5**:47–55.
47. DICHTER GS, DAMIANO CA, ALLEN JA. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. *J Neurodev Disord* 2012;**4**.
48. ELMAN I, SIGLER M, KRONENBERG J et al. Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD). *Isr J Psychiatry Relat Sci* 1998;**35**:280–286.
49. MARDER SR, FENTON W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. *Schizophr Res* 2004;**72**:5–9.
50. LINDENMAYER J-P, NASRALLAH H, PUCCI M, JAMES S, CITROME L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. *Schizophr Res* 2013;**147**:241–252.
51. BARCH DM, CARTER CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. *Schizophr Res* 2005;**77**:43–58.
52. LIEBERMAN JA, KANE JM, ALVIR J. Provocative tests with psychostimulant drugs in schizophrenia. *Psychopharmacology* 1987;**91**:415–433.
53. KARATEKIN C, WHITE T, BINGHAM C. Shared and nonshared symptoms in youth-onset psychosis and ADHD. *J Atten Disord* 2010;**14**:121–131.
54. RAMOS-QUIROGA JA, NASILLO V, RICHARTE V et al. Criteria and concurrent validity of DIVA 2.0: a semi-structured diagnostic interview for adult ADHD. *J Atten Disord* 2016;**33**:S630.